KBI's PUREplatform™ is a game-changing microbial expression offering that redefines biopharmaceutical manufacturing. The platform leverages the proprietary PUREcoli™ strain and cutting-edge screening packages for unmatched efficiencies and optimized...
Read More
The recent operational consolidation of KBI Biopharma, Inc. and Selexis SA brings a streamlined approach to support customers in rapidly accelerating...
Platform leverages proprietary PUREcoli™ strain and cutting-edge screening packages for unmatched efficiencies and optimized production processes...
KBI’s new model will enhance operational efficiencies, drive strategic clarity, and accelerate innovation for global biopharma customers Sunnyvale,...
Durham, North Carolina (May 10, 2023) – KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced the appointment of Marykay...
Milestone affirms KBI and Selexis SA’s Geneva cGMP site is operational and running successfully. GENEVA, March 21, 2023 – KBI Biopharma, Inc. (KBI),...
KBI Biopharma is thrilled to announce that Patriot Park has been named a finalist in the 2023 ISPE Facility of the Year Awards (FOYA) in two...
Following the recent Sudan ebolavirus outbreak in Uganda, KBI is providing emergency support through global production efforts. DURHAM, NC (January...
Major regulatory milestone demonstrates compliance with stringent standards for cGMP drug substance manufacturing. GENEVA, December 20, 2022– KBI...
What a year 2022 turned out to be! It was a year of growth and expansion, from the launch of our new KBI commercial manufacturing facility in...
